Skip to main content
GLSI logo

Greenwich LifeSciences, Inc.

GLSINASDAQHealthcareBiotechnology

$15.32Today:- (-)1Y +61.43%

As of Oct 15, 2026 close

Market cap
$224.00M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$7.78$34.10
Volume (live)
-
Avg. volume (3M)
127.46K

Greenwich LifeSciences (GLSI) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Greenwich LifeSciences used $9.91M of cash in operating activities and spent $3.00 on capital expenditures. That left free cash flow of −$9.91M.

Greenwich LifeSciences Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Greenwich LifeSciences, Inc. (GLSI) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-19.36-15.79-8.89-7.83-4.57-1.86-3.43-1.69-1.57
Depreciation & Amortization0.000.000.000.000.000.000.000.000.00
Deferred Income Tax0.000.000.00-1.75-1.19-0.780.000.000.00
Stock Based Compensation6.807.252.381.740.660.680.190.000.00
Change in Working Capital2.641.270.03-0.12-0.390.032.931.571.45
Change in Accounts Payable2.070.920.040.00-0.53-0.090.390.080.14
Change in Other Working Capital0.570.340.00-0.120.140.122.541.491.30
Other Operating Activities0.000.000.001.751.190.780.00-0.07-0.14
Net Cash from Operating Activities-9.91-7.27-6.48-6.20-4.29-1.15-0.29-0.11-0.12
Investing Activities
Capital Expenditures0.000.000.000.000.000.000.000.000.00
Net Cash from Investing Activities0.000.000.000.000.000.000.000.000.00
Financing Activities
Debt Repayment0.000.000.000.00-0.28-0.360.000.000.00
Common Stock Issued11.854.370.000.003.1130.170.000.100.00
Common Stock Repurchased0.000.000.00-7.540.000.000.000.00-0.09
Other Financing Activities0.000.000.000.00-0.25-0.360.220.20-0.13
Net Cash from Financing Activities12.004.370.00-7.542.8429.810.220.20-0.13
Summary
Net Change in Cash2.09-2.90-6.48-13.74-1.4628.65-0.080.09-0.25
Cash at Beginning of Period4.096.9913.4727.2028.660.010.090.000.25
Cash at End of Period6.184.096.9913.4727.2028.660.010.090.00
Free Cash Flow-9.91-7.27-6.48-6.20-4.29-1.15-0.29-0.11-0.12

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Greenwich LifeSciences Cash Flow

What is Greenwich LifeSciences's free cash flow?

Greenwich LifeSciences had negative free cash flow of $9.91M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$9.91M minus $3.00 of capital expenditures.

How much does Greenwich LifeSciences spend on capital expenditures?

Greenwich LifeSciences spent $3.00 on capital expenditures in fiscal 2025, compared with $3.00 a year earlier.

Does Greenwich LifeSciences pay dividends or buy back shares?

Greenwich LifeSciences's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition